This is in line with the evidence of the central role of inflammatory pathways in liver fibrosis progression in MASLD and suggests that epigenetic changes affecting SOCS3 could impact the expression of cytokines primarily involved in inflammation and fibrogenesis, such as IL-6 and MCP-1. The gene discussed is SOCS3; the disease is metabolic dysfunction-associated steatotic liver disease.